A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
At the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis on May 28-31 in Dallas, Acorda Therapeutics will be demonstrating its award-winning MS self™ mobile app designed for patients with multiple sclerosis.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recently offered a positive opinion for the marketing authorization of Biogen Idec’s Plegridy therapy, a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The positive opinion will now be sent to the European Commission, which grants…
The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc. lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy (PML). According to the National Institute of Neurological Disorders and Stroke, PML affects the white matter of the brain usually through a virus known as Polyomavirus JC (JC…
Cambridge, Massachusetts based biotech firm Genzyme has formed a new research collaboration with Cleveland Clinic of Cleveland, Ohio with a focus on developing new therapeutic approaches to the treatment of Multiple Sclerosis (MS). More than 2.3 million people worldwide have been diagnosed with MS, including what is believed…
New classes of pharmaceutical agents tailored to fight autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis, may be identified more effectively by adding genome analysis to standard drug screening, according to results of a new study by a collaborative research team led by UC San Francisco and…
Researchers from the Kessler Foundation have found that higher educational achievement reduces the negative impact of traumatic brain injury (TBI) on cognitive status. The study appeared in Archives of Physical Medicine & Rehabilitation. It was reported in the study that cognitive ability after experiencing TBI differs in individuals even when their injury levels were comparable. As…
Steve Pepple / Shutterstock.com The 2012 state ballot approvals of marijuana legalization in Colorado and Washington has been a catalyst for stirring the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a…
Get regular updates to your inbox.
